Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice

Experimental Neurology

Volumn 223, Issue 2, 2010, Pages 599-608

  Bruna, Jordi ^a,b,c   Udina, Esther ^a,b   Alé, Albert ^a   Vilches, Jorge J ^a   Vynckier, Ann ^d   Monbaliu, Johan ^d   Silverman, Lee ^e   Navarro, Xavier ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d JOHNSON AND JOHNSON   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bortezomib; Chemotherapy induced peripheral neuropathy; Mice; Neuropathy; Proteasome inhibitor

Indexed keywords

BORTEZOMIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOTOR NERVE CONDUCTION; MOUSE; MYELINATED NERVE; NERVE POTENTIAL; NOCICEPTION; NONHUMAN; NONMYELINATED NERVE; PAIN THRESHOLD; PRIORITY JOURNAL; SCIATIC NERVE; SENSORIMOTOR FUNCTION; SENSORY NERVE CONDUCTION; SENSORY NEUROPATHY; SKIN NERVE; SPINAL GANGLION; TIBIAL NERVE;

EID: 77952544961     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.02.006     Document Type: Article

References (53)

1. Argyriou A.A., Iconomou G., Kalofonos H.P. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008, 112:1593-1599.
2. Averill S., Michael G.J., Shortland P.J., Leavesley R.C., King V.R., Bradbury E.J., McMahon S.B., Priestley J.V. NGF and GDNF ameliorate the increase in ATF3 expression which occurs in dorsal root ganglion cells in response to peripheral nerve injury. Eur. J. Neurosci. 2004, 19:1437-1445.
3. Awada A., Albanell J., Canney P.A., Dirix L.Y., Gil T., Cardoso F., Gascon P., Piccart M.J., Baselga J. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br. J. Cancer 2008, 98:1500-1507.
4. Badros A., Goloubeva O., Dalal J.S., Can I., Thompson J., Rapoport A.P., Heyman M., Akpek G., Fenton R.G. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007, 110:1042-1049.
5. Bang S.M., Lee J.H., Yoon S.S., Park S., Min C.K., Kim C.C., Suh C., Sohn S.K., Min Y.H., Lee J.J., Kim K., Seong C.M., Yoon H.J., Cho K.S., Jo D.Y., Lee K.H., Lee N.R., Kim C.S. A multicenter retrospective analysis of adverse events in Korean patients using bortezomib for multiple myeloma. Int. J. Hematol. 2006, 83:309-313.
6. Caponigro F., Lacombe D., Twelves C., Bauer J., Govaerts A.S., Marreaud S., Milano A., Anthoney A. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur. J. Cancer 2009, 45:48-55.
7. Casafont I., Berciano M.T., Lafarga M. Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons. Neurotox. Res. 2010, 17:167-178.
8. Casals-Diaz L., Vivo M., Navarro X. Nociceptive responses and spinal plastic changes of afferent C-fibers in three neuropathic pain models induced by sciatic nerve injury in the rat. Exp. Neurol. 2009, 217:84-95.
9. Cata J.P., Weng H.R., Burton A.W., Villareal H., Giralt S., Dougherty P.M. Quantitative sensory findings in patients with bortezomib-induced pain. J. Pain 2007, 8:296-306.
10. Cavaletti G., Gilardini A., Canta A., Rigamonti L., Rodriguez-Menendez V., Ceresa C., Marmiroli P., Bossi M., Oggioni N., D'Incalci M., De C.R. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp. Neurol. 2007, 204:317-325.
11. Chao T., Pham K., Steward O., Gupta R. Chronic nerve compression injury induces a phenotypic switch of neurons within the dorsal root ganglia. J. Comp. Neurol. 2008, 506:180-193.
12. Chaudhry V., Cornblath D.R., Polydefkis M., Ferguson A., Borrello I. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J. Peripher. Nerv. Syst. 2008, 13:275-282.
13. Davies A.M., Chansky K., Lara P.N., Gumerlock P.H., Crowley J., Albain K.S., Vogel S.J., Gandara D.R. Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J. Thorac. Oncol. 2009, 4:87-92.
14. Gómez N., Cuadras J., Batí M., Navarro X. Histologic assessment of sciatic nerve regeneration following resection and graft or tube repair in the mouse. Restor. Neurol. Neurosci. 1996, 10:187-196.
15. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32:77-88.
16. Harousseau J.L., Attal M., Leleu X., Troncy J., Pegourie B., Stoppa A.M., Hulin C., Benboubker L., Fuzibet J.G., Renaud M., Moreau P., vet-Loiseau H. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91:1498-1505.
17. Holland N.R., Crawford T.O., Hauer P., Cornblath D.R., Griffin J.W., McArthur J.C. Small-fiber sensory neuropathies: clinical course and neuropathology of idiopathic cases. Ann. Neurol. 1998, 44:47-59.
18. Jackson G., Einsele H., Moreau P., Miguel J.S. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat. Rev. 2005, 31:591-602.
19. Jagannath S., Barlogie B., Berenson J., Siegel D., Irwin D., Richardson P.G., Niesvizky R., Alexanian R., Limentani S.A., Alsina M., Adams J., Kauffman M., Esseltine D.L., Schenkein D.P., Anderson K.C. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. 2004, 127:165-172.
20. Jagannath S., Barlogie B., Berenson J.R., Siegel D.S., Irwin D., Richardson P.G., Niesvizky R., Alexanian R., Limentani S.A., Alsina M., Esseltine D.L., Anderson K.C. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br. J. Haematol. 2008, 143:537-540.
21. Kane R.C., Dagher R., Farrell A., Ko C.W., Sridhara R., Justice R., Pazdur R. Bortezomib for the treatment of mantle cell lymphoma. Clin. Cancer Res. 2007, 13:5291-5294.
22. Lago N., Navarro X. Evaluation of the long-term regenerative potential in an experimental nerve amputee model. J. Peripher. Nerv. Syst. 2007, 12:108-120.
23. Li X.Q., Verge V.M., Johnston J.M., Zochodne D.W. CGRP peptide and regenerating sensory axons. J. Neuropathol. Exp. Neurol. 2004, 63:1092-1103.
24. Ludwig H., Khayat D., Giaccone G., Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer 2005, 104:1794-1807.
25. Mateos M.V., Hernandez J.M., Hernandez M.T., Gutierrez N.C., Palomera L., Fuertes M., Garcia-Sanchez P., Lahuerta J.J., de la R.J., Terol M.J., Sureda A., Bargay J., Ribas P., Alegre A., de A.F., Oriol A., Carrera D., Garcia-Larana J., Garcia-Sanz R., Blade J., Prosper F., Mateo G., Esseltine D.L., van d.V., San Miguel J.F. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica 2008, 93:560-565.
26. Meregalli C., Canta A, Carozzi V.A., Chiorazzi A., Oggioni N., Gilardini A., Ceresa C., Avezza F., Crippa L., Marmiroli P., Cavaletti G. Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats. Eur. J. Pain. 2009, 14:343-350.
27. Miki K., Fukuoka T., Tokunaga A., Noguchi K. Calcitonin gene-related peptide increase in the rat spinal dorsal horn and dorsal column nucleus following peripheral nerve injury: up-regulation in a subpopulation of primary afferent sensory neurons. Neuroscience 1998, 82:1243-1252.
28. Min C.K., Lee M.J., Eom K.S., Lee S., Lee J.W., Min W.S., Kim C.C., Kim M., Lim J., Kim Y., Han K. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone. Jpn. J. Clin. Oncol. 2007, 37:961-968.
29. Molliver D.C., Wright D.E., Leitner M.L., Parsadanian A.S., Doster K., Wen D., Yan Q., Snider W.D. IB4-binding DRG neurons switch from NGF to GDNF dependence in early postnatal life. Neuron 1997, 19:849-861.
30. Nandi D., Tahiliani P., Kumar A., Chandu D. The ubiquitin-proteasome system. J. Biosci. 2006, 31:137-155.
31. Navarro X., Verdu E., Guerrero J., Buti M., Gonalons E. Abnormalities of sympathetic sudomotor function in experimental acrylamide neuropathy. J. Neurol. Sci. 1993, 114:56-61.
32. Navarro X., Verdu E., Buti M. Comparison of regenerative and reinnervating capabilities of different functional types of nerve fibers. Exp. Neurol. 1994, 129:217-224.
33. Navarro X., Verdú E., Wendelschafer-Crabb G., Kennedy W.R. Innervation of cutaneous structures in the mouse hindpaw: a confocal microscopy immunocytochemical study. J. Neurosci. Res. 1995, 41:111-120.
34. Nishigami T., Osako Y., Tanaka K., Yuri K., Kawasaki M., Ikemoto T., McLaughlin M., Ishida K., Tani T., Ushida T. Changes in calcitonin gene-related peptide expression following joint immobilization in rats. Neurosci. Lett. 2009, 454:97-100.
35. Ohtori S., Inoue G., Koshi T., Ito T., Yamashita M., Yamauchi K., Suzuki M., Doya H., Moriya H., Takahashi Y., Takahashi K. Characteristics of sensory dorsal root ganglia neurons innervating the lumbar vertebral body in rats. J. Pain 2007, 8:483-488.
36. Pan C.L., Lin Y.H., Lin W.M., Tai T.Y., Hsieh S.T. Degeneration of nociceptive nerve terminals in human peripheral neuropathy. Neuroreport 2001, 12:787-792.
37. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
38. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., Rajkumar S.V., Srkalovic G., Alsina M., Alexanian R., Siegel D., Orlowski R.Z., Kuter D., Limentani S.A., Lee S., Hideshima T., Esseltine D.L., Kauffman M., Adams J., Schenkein D.P., Anderson K.C. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003, 348:2609-2617.
39. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San-Miguel J.F., Blade J., Boccadoro M., Cavenagh J., Dalton W.S., Boral A.L., Esseltine D.L., Porter J.B., Schenkein D., Anderson K.C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2005, 352:2487-2498.
40. Richardson P.G., Briemberg H., Jagannath S., Wen P.Y., Barlogie B., Berenson J., Singhal S., Siegel D.S., Irwin D., Schuster M., Srkalovic G., Alexanian R., Rajkumar S.V., Limentani S., Alsina M., Orlowski R.Z., Najarian K., Esseltine D., Anderson K.C., Amato A.A. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J. Clin. Oncol. 2006, 24:3113-3120.
41. Richardson P.G., Xie W., Mitsiades C., Chanan-Khan A.A., Lonial S., Hassoun H., Avigan D.E., Oaklander A.L., Kuter D.J., Wen P.Y., Kesari S., Briemberg H.R., Schlossman R.L., Munshi N.C., Heffner L.T., Doss D., Esseltine D.L., Weller E., Anderson K.C., Amato A.A. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol. 2009, 27:3518-3525.
42. San Miguel J.F., Schlag R., Khuageva N.K., Dimopoulos M.A., Shpilberg O., Kropff M., Spicka I., Petrucci M.T., Palumbo A., Samoilova O.S., Dmoszynska A., Abdulkadyrov K.M., Schots R., Jiang B., Mateos M.V., Anderson K.C., Esseltine D.L., Liu K., Cakana A., van d.V., Richardson P.G. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 2008, 359:906-917.
43. Shao Y., Gao Z., Marks P.A., Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:18030-18035.
44. Shimizu S., Kanaseki T., Mizushima N., Mizuta T., rakawa-Kobayashi S., Thompson C.B., Tsujimoto Y. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat. Cell Biol. 2004, 6:1221-1228.
45. Shintani T., Klionsky D.J. Autophagy in health and disease: a double-edged sword. Science 2004, 306:990-995.
46. Silverman L., Csizmadia L., Kadambi V.J., Decoster R., Vynckier A., Jortner B., Alden C.L. Model for proteasome inhibition associated peripheral neuropathy. Toxicol. Pathol. 2006, 34:989.
47. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., Langer C., Murphy B., Cumberlin R., Coleman C.N., Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 2003, 13:176-181.
48. Verdu E., Vilches J.J., Rodriguez F.J., Ceballos D., Valero A., Navarro X. Physiological and immunohistochemical characterization of cisplatin-induced neuropathy in mice. Muscle Nerve 1999, 22:329-340.
49. Vilches J.J., Navarro X. New silicones for the evaluation of sudomotor function with the impression mold technique. Clin. Auton. Res. 2002, 12:20-23.
50. Voorhees P.M., Dees E.C., O'Neil B., Orlowski R.Z. The proteasome as a target for cancer therapy. Clin. Cancer Res. 2003, 9:6316-6325.
51. Xu P., Van S.C., Berti-Mattera L., Hall A.K. Activin induces tactile allodynia and increases calcitonin gene-related peptide after peripheral inflammation. J. Neurosci. 2005, 25:9227-9235.
52. Zhao Z., Alam S., Oppenheim R.W., Prevette D.M., Evenson A., Parsadanian A. Overexpression of glial cell line-derived neurotrophic factor in the CNS rescues motoneurons from programmed cell death and promotes their long-term survival following axotomy. Exp. Neurol. 2004, 190:356-372.
53. Zheng L.F., Wang R., Xu Y.Z., Yi X.N., Zhang J.W., Zeng Z.C. Calcitonin gene-related peptide dynamics in rat dorsal root ganglia and spinal cord following different sciatic nerve injuries. Brain Res. 2008, 1187:20-32.